---
title: "Yatai Pharm released its performance for the first three quarters, with a net profit attributable to the parent company of 97.195 million yuan, a year-on-year increase of 2909.49%"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/263088786.md"
description: "According to the Zhitong Finance APP, Yatai Pharm released its third-quarter report for 2025. In the first three quarters, the company achieved an operating income of 228 million yuan, a year-on-year decrease of 25.59%. The net profit attributable to shareholders of the listed company was 97.195 million yuan, a year-on-year increase of 2909.49%. The net loss attributable to shareholders of the listed company, after deducting non-recurring gains and losses, was 56.5853 million yuan"
datetime: "2025-10-28T12:36:03.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/263088786.md)
  - [en](https://longbridge.com/en/news/263088786.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/263088786.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/263088786.md) | [繁體中文](https://longbridge.com/zh-HK/news/263088786.md)


# Yatai Pharm released its performance for the first three quarters, with a net profit attributable to the parent company of 97.195 million yuan, a year-on-year increase of 2909.49%

According to the Zhitong Finance APP, Yatai Pharm (002370.SZ) released its third-quarter report for 2025. In the first three quarters, the company achieved an operating income of 228 million yuan, a year-on-year decrease of 25.59%. The net profit attributable to shareholders of the listed company was 97.195 million yuan, a year-on-year increase of 2909.49%. The net loss attributable to shareholders of the listed company, after deducting non-recurring gains and losses, was 56.5853 million yuan

### Related Stocks

- [Yatai pharm (002370.CN)](https://longbridge.com/en/quote/002370.CN.md)

## Related News & Research

- [China Medical System Gets China Nod to Market Renal Anaemia Drug](https://longbridge.com/en/news/279046722.md)
- [Clover Biopharmaceuticals Sets Board Meeting to Approve 2025 Results and Consider Dividend](https://longbridge.com/en/news/279032574.md)
- [Điện Máy Xanh plans IPO amid parent company retail overhaul](https://longbridge.com/en/news/279034524.md)
- [Kennedy Center President Grenell to transition out of his role, Axios reports](https://longbridge.com/en/news/279085698.md)
- [Know a rising star in pharma marketing? Nominate them here](https://longbridge.com/en/news/278461777.md)